← Back to patent-cliff list
BEBT-209
Tier C — Watch / tradeBEBT-209
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：CDK6, CDK4
Indications (approved)：三阴性乳腺癌, Breast cancer, Metastatic breast cancer
Regional status
US
-
EU
-
China
Phase III
2022-06-09
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of BEBT-209?
Approved indications include: 三阴性乳腺癌, Breast cancer, Metastatic breast cancer.
When does the BEBT-209 patent expire?
No public expiry year is available for BEBT-209 yet; this page updates once verified.
How do I get a quote for BEBT-209 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-05